Literature DB >> 34287805

Pamiparib: First Approval.

Anthony Markham1.   

Abstract

Pamiparib (PARTRUVIX™; BeiGene Ltd.) is a selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor being developed for the treatment of various cancers. Based on the results from the pivotal phase II portion of a phase I/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy. This article summarizes the milestones in the development of pamiparib leading to this first approval.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34287805     DOI： 10.1007/s40265-021-01552-8

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  3 in total

1.  The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.

Authors:  Song Mu; Chester Lin; Anna Skrzypczyk-Ostaszewicz; Iurie Bulat; Marina Maglakelidze; Viera Skarbova; Claudia Andreu-Vieyra; Srikumar Sahasranaman
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-27       Impact factor: 3.333

2.  A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.

Authors:  Yanmei Wu; Xiaodong Pan; Juan Dou; Quan Zhang; Yuantong Li; Yuan Sheng; Xishui Liu
Journal:  Clin Med Insights Oncol       Date:  2021-07-02

3.  Human Mass Balance and Metabolite Profiling of [14 C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.

Authors:  Song Mu; Daniel Palmer; Richard Fitzgerald; Claudia Andreu-Vieyra; Heather Zhang; Zhiyu Tang; Dan Su; Srikumar Sahasranaman
Journal:  Clin Pharmacol Drug Dev       Date:  2021-04-19
  3 in total
  7 in total

Review 1.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13

Review 2.  Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.

Authors:  Liesbeth Everix; Shankari Nair; Cathryn H S Driver; Ingeborg Goethals; Mike M Sathekge; Thomas Ebenhan; Charlot Vandevoorde; Julie Bolcaen
Journal:  Cancers (Basel)       Date:  2022-04-03       Impact factor: 6.639

Review 3.  Opinion: PARP inhibitors in cancer-what do we still need to know?

Authors:  Andrew J Wicks; Dragomir B Krastev; Stephen J Pettitt; Andrew N J Tutt; Christopher J Lord
Journal:  Open Biol       Date:  2022-07-27       Impact factor: 7.124

Review 4.  Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma.

Authors:  Ioannis Ntafoulis; Stijn L W Koolen; Sieger Leenstra; Martine L M Lamfers
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

5.  A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers.

Authors:  Tingting Du; Zhihui Zhang; Jie Zhou; Li Sheng; Haiping Yao; Ming Ji; Bailing Xu; Xiaoguang Chen
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

Review 6.  Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Authors:  Tao Xie; Kristie-Ann Dickson; Christine Yee; Yue Ma; Caroline E Ford; Nikola A Bowden; Deborah J Marsh
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

Review 7.  PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Authors:  Clifford M Csizmar; Antoine N Saliba; Elizabeth M Swisher; Scott H Kaufmann
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.